NORTHWEST BIOTHERAPEUTICS INC
Close on Oct 19, 2026
- Market cap
- $254.79M
- P/E (TTM)
- –
- Dividend yield
- –
About Northwest Biotherapeutics
Pharmaceutical Preparations, SIC 2834
Northwest Biotherapeutics is a biotechnology company that develops personalized immune therapies for cancer patients. Its platform technology, DCVax, utilizes a patient's activated dendritic cells to stimulate their immune system against cancer. The company's lead product candidate, DCVax-L, targets surgically removable solid tumors such as glioblastoma multiforme brain cancer. Another product candidate, DCVax-Direct, is designed to treat inoperable solid tumors across a range of cancer types. The company operates within the biopharmaceutical sector, focusing on cancer patients.
The company is headquartered in Bethesda, Maryland. Its operations include a specialized manufacturing facility located in Sawston, United Kingdom. Northwest Biotherapeutics holds intellectual property and has conducted clinical trials across the United States, Europe, and Japan. As of late 2025, the company maintains 105 full-time employees, supplemented by specialized consultants and a contracted workforce supporting its international operations in the United Kingdom.
Summary of the business section of Northwest Biotherapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NORTHWEST BIOTHERAPEUTICS INC
- Founded
- 1996
- Headquarters
- Bethesda, MD
- Address
- 4800 Montgomery Lane, Suite 800 20814
- Phone
- (240) 497-9024
- Website
- nwbio.com
- Employees
- 105, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Cherry Bekaert LLP, Nashville, Tennessee
Stock & identifiers
- Ticker
- NWBO
- Exchange
- OTC
- IPO date
- Dec 14, 2001
- Shares outstanding
- 1.71B, Aug 13, 2026
- Public float
- $340.24M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-16000 reverse, Nov 14, 2012; 1-for-16 reverse, Sep 26, 2012; 1-for-15 reverse, Jun 28, 2007
- SEC CIK
- 1072379
- CUSIP
- 66737P600
- ISIN
- US66737P6007
- LEI
- 5493002DRWWEOWTT8005
- EIN
- 94-3306718
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Northwest Biotherapeutics's leadership is listed in its proxy statement, last filed Nov 28, 2025.
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Linda Powers | $1.23M | $1.23M | $804.00K | $39 | – |
| FY2023 Linda Powers | $1.23M | $1.23M | $804.00K | $100 | – |
| FY2022 Linda Powers | $1.10M | $1.10M | $711.00K | $111 | – |
| FY2021 Linda Powers | $1.00M | $31.00K | $646.00K | $170 | $158 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 105 full-time employees.”
Corporate history
Events identified from SEC filings